« Go Back

Thomas W. Davis, Ph.D.

Thomas Davis is Vice President of Biology at Recludix Pharma and has over 20 years of experience in small molecule drug development, primarily in oncology and inflammation. Dr. Davis started his career in academia at Case Western Reserve University but was recruited to join Pharmacia Corporation to explore the potential of the new COX2-selective inhibitor celecoxib as an antiangiogenic, an extension of his doctoral work. While there, his team also generated in vivo efficacy data for the kinase inhibitors from Sugen, including sunitinib. Upon the Pfizer acquisition of Pharmacia, Dr. Davis joined PTC Therapeutics. As Vice President of Preclinical Oncology, he led their efforts in oncology, resulting in the development of PTC299 (for various liquid cancers) and PTC596 (for pediatric brain cancer), which are both currently in clinical development. Prior to joining Recludix, Dr. Davis was the Vice President of Biology at PMV Pharma where he worked on the mutant p53 reactivator PMV586 (for patients harboring the Y220C p53 mutation), which is currently in clinical development. Dr. Davis holds a Ph.D. in Microbiology and Immunology from the University of Kentucky.